EGFR and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), activating mutations of EGFR in exons 18–21 are well established as predictive biomarkers for treatment of patients with EGFR tyrosine kinase inhibitors (TKIs) [1].